Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

NCT07551414 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Carcinoma)
Leptomeningeal Metastasis
EGFR-TKI Sensitizing Mutation
Zorifertinib

Interventions

DRUG: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]